9 stories found
The American Society of Clinical Oncology (ASCO) World Congress has unveiled new data regarding highly personalized treatments for breast cancer, setting a roadmap for global cancer care.
The American Society of Clinical Oncology highlights the power of molecular alterations in a tumor's 'signature' for guiding treatment and determining prognosis in precision oncology.
An international trial presented at the American Society of Clinical Oncology congress revealed that a new drug, daraxonrasib, significantly increases survival rates for patients with metastatic pancreatic tumors, with France also rolling out a prevention program.
Optimistic messages regarding the therapeutic treatment of resistant and advanced forms of cancer emerged from the annual ASCO (American Society of Clinical Oncology) conference, held from May 29 to June 2 in Chicago.
A new therapeutic development announced at the American Society of Clinical Oncology (ASCO) conference is being hailed as a revolution in oncology, as it reportedly doubles the life expectancy for patients with metastatic pancreatic cancer from 6.7 to 13.2 months.
An international trial presented at the American Society of Clinical Oncology congress revealed that Revolution's new drug, daraxonrasib, significantly increases survival rates and boosts quality of life for patients with metastatic pancreatic tumors, with France also rolling out a prevention program.
The annual American Society of Clinical Oncology (ASCO) conference highlighted significant advances in cancer treatment, including a new pill that reportedly doubles life expectancy and a summary of five other crucial clinical studies.
A significant study presenting a new therapeutic approach for non-metastatic prostate cancer was announced at the American Society of Clinical Oncology (ASCO) conference, held in Chicago from May 29, 2026. The findings are expected to change current treatment methods.
Korean company ViGenCell has been selected to deliver an official oral presentation at the upcoming American Society of Clinical Oncology annual meeting, marking a first for a Korean company regarding clinical studies of a cell therapy.